INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]

Similar documents
CPT Service Description Effective Date

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Subject: Palonosetron Hydrochloride (Aloxi )

PA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*

Part B payment for drugs in Medicare 0

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Drug Use Evaluation: Physician Administered Drugs (PADs)

Provider Newsletter. Table of Contents. Reimbursement Policy: Improve member medication regimen. Page 2

MEDICAL NECESSITY GUIDELINE

Part B payment for drugs in Medicare 0

intolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra*

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Injections Requiring Prior Authorization

Welcome. Coding uidelines Coding Guidelines Coding. Coding Guidelines Coding Guidelines. Contact Us. Edition #1 March 2018

Re: Integrated Oncology Management Program with evicore healthcare: Update on codes requiring precertification

The following are J Code requirements

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Adult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Leukemia. Treatment of. compendia. Associated ICD-9-CM Codes: Drug & Administration. managedcareoncology.com

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

Contents Please refer to Medical Policy I-4, Hemophilia Treatment for additional information.

Guideline Update on Antiemetics

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

CANCER IMMUNOTHERAPY: A REVIEW

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

NEW FDA DRUG APPROVALS

Corporate Medical Policy

Change Healthcare Clinical Evidence Classification

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

NEW FDA DRUG APPROVALS

Health Partners Medicare Special Formulary Updates

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

Targeted Cancer Therapies

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care

Haematology, Oncology and Palliative Care Directorate.

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it

Cigna Drug and Biologic Coverage Policy

Cancer Therapy Update in 2017

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class

See Important Reminder at the end of this policy for important regulatory and legal information.

New Immunotherapies Prior to Stem Cell Transplant

Melanoma. compendia. Associated ICD-9-CM Codes: Drug & Administration

September 2018 Pharmacy & Therapeutics Committee Decisions

MASCC Guidelines for Antiemetic control: An update

To help doctors give their patients the best possible care, the American

Our Clinical Trials. Oncology

Pharmacology Update. Power. Note one action you ll take after attending this session:

Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

New Developments in Cancer Treatment. Dulcinea Quintana, MD

RETIRED. Maximum Drug Dose Policy

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC

Ovarian Cancer. compendia TREATMENT OF

Medications currently available to treat Multiple Myeloma include: Current Code Price (AWP) Effective Date. Code Price (AWP)

Updates to Medical Policies and Clinical UM Guidelines

Coding Tips, Hints & Pointers for Medical Oncology Billing

CLINICAL TRIALS ACC. Jul 2016

Lecture 8: Antibodies & Antibody Conjugates - targeted cell killing agents

Managements of Chemotherpay Induded Nausea and Vomiting

Phase 1 HEMATOLOGY. GI- 219: BBI (pending 1 st Qtr) Phase Ib Therapeutic BBI608 provided

THE DUDLEY GROUP NHS FOUNDATION TRUST FOI

Medicare Part C Medical Coverage Policy

Corporate Medical Policy

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

Corporate Medical Policy

Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue

National Cancer Drugs Fund List - Approved

See Important Reminder at the end of this policy for important regulatory and legal information.

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

ADCs The year in review and 2018 outlook

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

Dose Rounding of Cytotoxic Drugs and Monoclonal Antibodies. A Position Statement of the Hematology/Oncology Pharmacy Association

Global Oncology Trends 2017

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

Outpatient Payment. Agenda 2/2/2013. Medicare Outpatient. Payment Basics

Northern Cancer Alliance

Transcription:

Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April, July, and October. NOTE: Unlisted and Miscellaneous health service codes should only be used if a specific code has not been established by the American Medical Association. (Note: Services for Blue Medicare HMO and Blue Medicare PPO members require prior review as of 9/1/2010.) Notice Date: The listed date is when the notice of the existing code was added. Effective Date: The listed date is when the code will require prior authorization for correct claims processing. If there is no date in this field, the requirement is in effect. Ineffective Date: The listed date is when the code became invalid. The code can be billed for up to 18 months past the date for correct claims processing if prior authorization was requested. *Prior approval is required for all drugs listed below regardless of the HCPCS code submitted on the claim. The requirement is based on the drug itself not the code chosen to submit on the claim. CPT Service Description Effective Date Notice Date Date Ineffective C9028 INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY] 1/1/2018 12/29/2017 C9030 INJECTION, COPANLISIB, 1 MG [ALIQOPA ] [C CODES FOR FACILITY USE 10/1/2018 7/1/2018 ONLY] C9463 INJECTION, APREPITANT, 1 MG [C CODES FOR FACILITY USE ONLY] C9464 INJECTION, ROLAPITANT, 0.5 MG [C CODES FOR FACILITY USE ONLY] C9467 SUBCUTANEOUS USE [RITUXAN HYCELA ] [C CODES FOR FACILITY USE ONLY] J0881 INJECTION, DARBEPOETIN ALFA, 1 MCG (NON-ESRD USE) 4/1/2017 12/30/2016 J0885 INJECTION, EPOETIN ALFA, (NON-ESRD USE), 1000 UNITS 4/1/2017 12/30/2016 J0897 INJECTION, DENOSUMAB, 1 MG 4/1/2017 12/30/2016

J1442 INJECTION, FILGRASTIM (G-CSF), EXCLUDES BIOSIMILARS, 1 MICROGRAM 4/1/2017 12/30/2016 J1453 INJECTION, FOSAPREPITANT, 1 MG 4/1/2017 12/30/2016 J1447 INJECTION, TBO-FILGRASTIM, 1 MICROGRAM 4/1/2017 12/30/2016 J1627 INJECTION, GRANISETRON, EXTENDED-RELEASE, 0.1 MG J2469 INJECTION, PALONOSETRON HCL, 25 MCG 4/1/2017 12/30/2016 J2505 INJECTION, PEGFILGRASTIM, 6 MG 4/1/2017 12/30/2016 J2820 INJECTION, SARGRAMOSTIM (GM-CSF), 50 MCG 4/1/2017 12/30/2016 J2860 INJECTION, SILTUXIMAB, 10 MG 4/1/2017 12/30/2016 J9022 INJECTION, ATEZOLIZUMAB, 10 MG [TECENTRIQ ] 1/1/2018 10/1/2016 J9023 INJECTION, AVELUMAB, 10 MG [BAVENCIO ] 4/1/2018 12/29/2017 J9035 INJECTION, BEVACIZUMAB, 10 MG 4/1/2017 12/30/2016 J9039 INJECTION, BLINATUMOMAB, 1 MG 1/1/2018 10/1/2017 J9042 INJECTION, BRENTUXIMAB VEDOTIN, 1 MG 4/1/2017 12/30/2016 J9043 INJECTION, CABAZITAXEL, 1 MG 4/1/2017 12/30/2016 J9047 INJECTION, CARFILZOMIB, 1 MG 4/1/2017 12/30/2016 J9055 INJECTION, CETUXIMAB, 10 MG 4/1/2017 12/30/2016 J9145 INJECTION, DARATUMUMAB, 10 MG 4/1/2017 12/30/2016 J9176 INJECTION, ELOTUZUMAB, 1 MG 4/1/2017 12/30/2016 J9179 INJECTION, ERIBULIN MESYLATE, 0.1 MG 4/1/2017 12/30/2016 J9202 GOSERELIN ACETATE IMPLANT, PER 3.6 MG 4/1/2017 12/30/2016

J9203 INJECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG [MYLOTARG ] 4/1/2018 12/29/2017 J9228 INJECTION, IPILIMUMAB, 1 MG 4/1/2017 12/30/2016 J9264 INJECTION, PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG 4/1/2017 12/30/2016 J9271 INJECTION, PEMBROLIZUMAB, 1 MG 4/1/2017 12/30/2016 J9285 INJECTION, OLARATUMAB, 10 MG [LARTUVO ] 4/1/2018 12/29/2017 J9295 INJECTION, NECITUMUMAB, 1 MG 4/1/2017 12/30/2016 J9299 INJECTION, NIVOLUMAB, 1 MG 4/1/2017 12/30/2016 J9301 INJECTION, OBINUTUZUMAB, 10 MG 4/1/2017 12/30/2016 J9302 INJECTION, OFATUMUMAB, 10 MG 4/1/2017 12/30/2016 J9303 INJECTION, PANITUMUMAB, 10 MG 4/1/2017 12/30/2016 J9305 INJECTION, PEMETREXED, 10 MG 4/1/2017 12/30/2016 J9306 INJECTION, PERTUZUMAB, 1 MG 4/1/2017 12/30/2016 J9310 INJECTION, RITUXIMAB, 100 MG 4/1/2017 12/30/2016 J9351 INJECTION, TOPOTECAN, 0.1 MG 4/1/2017 12/30/2016 J9354 INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG 4/1/2017 12/30/2016 J9355 INJECTION, TRASTUZUMAB, 10 MG 4/1/2017 12/30/2016 Q2043 SIPULEUCEL-T, MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PAP-GM-CSF, INCLUDING LEUKAPHERESIS AND ALL OTHER PREPARATORY PROCEDURES, PER INFUSION 4/1/2017 12/30/2016 Q5101 INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, 1 MICROGRAM 4/1/2017 12/30/2016

Q5106 INJECTION, EPOETIN ALFA, BIOSIMILAR, (RETACRIT) (NON-ESRD USE), 1000 UNITS 7/1/2018 7/1/2018 S0353 TREATMENT PLANNING AND CARE COORDINATION MANAGEMENT FOR CANCER INITIAL TREATMENT 4/1/2017 12/30/2016 S0354 TREATMENT PLANNING AND CARE COORDINATION MANAGEMENT FOR CANCER ESTABLISHED PATIENT WITH A CHANGE OF REGIMEN 4/1/2017 12/30/2016 ***AIM Specialty Health DOES review drugs with unlisted, miscellaneous, or unclassified codes (codes and drug names requiring prior review are listed below). *** Please, remember to ALWAYS refer to the Blue Cross NC Other Service and Procedures prior review list for prior review requirements. https://www.bcbsnc.com/assets/providers/public/pdfs/ppa-service-code-list.pdf J3490* UNCLASSIFIED DRUGS INJECTION, LIPOSOMAL, 1 MG DAUNORUBICIN AND 2.27 MG CYTARABINE [VYXEOS ] 4/1/2018 12/29/2017 ROLAPITANT INJECTABLE EMULSION, FOR INTRAVENOUS USE [VARUBI ] APREPITANT INJECTABLE EMULSION, FOR INTRAVENOUS USE [CINVANTI ] SUBCUTANEOUS USE [RITUXAN HYCELA ] INJECTION, COPANLISIB, 1 MG [ALIQOPA ] 10/1/2018 7/1/2018

DURVALUMAB (IMFINZI ) 4/1/2018 1/1/2018 J3590* UNCLASSIFIED BIOLOGICALS 1/1/2018 10/1/2017 INJECTION, LIPOSOMAL, 1 MG DAUNORUBICIN AND 2.27 MG CYTARABINE [VYXEOS ] 4/1/2018 12/29/2017 ROLAPITANT INJECTABLE EMULSION, FOR INTRAVENOUS USE [VARUBI ] APREPITANT INJECTABLE EMULSION, FOR INTRAVENOUS USE [CINVANTI ] SUBCUTANEOUS USE [RITUXAN HYCELA ] INJECTION, COPANLISIB, 1 MG [ALIQOPA ] 10/1/2018 7/1/2018 DURVALUMAB (IMFINZI ) 4/1/2018 1/1/2018 J9999* NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUGS INJECTION, LIPOSOMAL, 1 MG DAUNORUBICIN AND 2.27 MG CYTARABINE [VYXEOS ] 4/1/2018 12/29/2017 ROLAPITANT INJECTABLE EMULSION, FOR INTRAVENOUS USE [VARUBI ] APREPITANT INJECTABLE EMULSION, FOR INTRAVENOUS USE [CINVANTI ] DURVALUMAB (IMFINZI ) 4/12018 1/1/2018 SUBCUTANEOUS USE [RITUXAN HYCELA ] INJECTION, COPANLISIB, 1 MG [ALIQOPA ] 10/1/2018 7/1/2018

C9399* UNCLASSIFIED DRUGS OR BIOLOGICALS [C CODES FOR FACILITY USE ONLY] ROLAPITANT INJECTABLE EMULSION, FOR INTRAVENOUS USE [VARUBI ] DURVALUMAB (IMFINZI ) 4/1/2018 1/1/2018